Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00912301
Other study ID # 08-001003
Secondary ID R01DK054681R01DK
Status Completed
Phase Phase 2
First received May 29, 2009
Last updated May 29, 2012
Start date April 2009
Est. completion date December 2009

Study information

Verified date May 2012
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The study hypothesis is that the naturally occurring bile acid, chenodeoxycholic acid, induces acceleration of colonic transit in health and in patients with constipation-predominant Irritable Bowel Syndrome (IBS-C).


Description:

Hypothesis: A hydrophobic di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), delivered in a delayed release capsule to the ileocolonic region of the colon induces acceleration of colonic transit in patients with constipation-predominant IBS.

Methods: We shall study 36 patients with IBS-C, aged 18-65 years, and each treatment group will be balanced on gender and Body Mass Index (BMI) in the randomization. All patients will be assessed for symptoms of functional gastrointestinal disorder or psychological disturbance will be characterized in a standard fashion with questionnaires (Talley et al 1989), the Psychosomatic Symptom Checklist (SCL-90) and the Hospital Anxiety and Depression Inventory [HAD (Zigmond and Snaith 1983)]. With appropriate consent, a venous blood sample will be obtained from each participant for DNA extraction. Fasting Serum 7alpha-hydroxy-4-cholesten-3-one (7alpha-CHO) will be measured in all to ensure they do not have evidence of asymptomatic bile acid malabsorption. The normal range in our lab is <61 ng/mL.

Experimental design: A randomized, double blind, placebo controlled, dose-response parallel group design, with concealed allocation. Participants will undergo an initial baseline colonic transit for 24 hours to obtain Colonic Geometric Center (GC24). Sodium chenodeoxycholate (CDC) will be delivered to the ileocolonic region to assess ascending colon and whole colonic transit in participants with IBS-C; 12 participants per group will be randomized to placebo, 0.5 or 1 gram CDC each for a period of 4 days with the transit study conducted during the last 48 hours of drug ingestion. The CDC will be placed in gelatin capsules that are coated with methacrylate (EUDRAGIT-L®), a pH-sensitive polymer that will result in release of the active ingredient in the terminal ileum.

Experimental procedure: At standardized times (hourly for first 8 hours, and at 12, 24 and 48 h), dual gamma camera scans will be obtained to measure ascending colon and overall colonic transit. Patients will fill daily diaries to evaluate stool, frequency, consistency and ease of passage.

Gastrointestinal and Colonic Transit: A validated scintigraphic method to measure gastric, small bowel, and colonic transit will be used. A methacrylate-coated capsule dissolves in the alkaline pH of the distal ileum to release 111In-labeled activated charcoal particles to evaluate colonic transit on sequential scans. Meanwhile, orally ingested 99 mTc-labeled egg meal allows measurement of gastric and small bowel transit. (Technetium [99mTc] sestamibi (trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.) We have previously shown that the gastric emptying (GE) at 2 and 4 hours, colonic filling (CF) at 6 hours, and colonic geometric center (GC, weighted average of isotopic counts) in colon at 4, 24 and 48 hours provide excellent summaries of gastric emptying and colonic transit with similar diagnostic accuracy as more detailed, costly, and time-consuming analyses. The normal values for these parameters have been previously published (Cremonini et al).

Scintigraphic gastric emptying and intestinal/colonic transit analysis: A variable region of interest program will be used to measure transit, as in previous studies from our lab. Radioisotope content in each region (gastric, ascending, transverse, descending, rectosigmoid) will be corrected for decay and tissue attenuation or depth.

Anticipated Result: CDC will accelerate whole colonic transit and loosen stool form in patients with constipation predominant IBS.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 2009
Est. primary completion date November 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

Healthy volunteers:

- Age (yr) 18-65

- Gender (F:M)3.5 :1

- Bowel Disease Questionnaire (BDQ) - IBS symptoms negative by Rome III criteria

- Hospital Anxiety/Depression score <8

IBS patients:

- Age (yr) 18-65

- Gender (F:M) 5 :1

- BDQ - IBS symptoms: positive by Rome III criteria

- Hospital Anxiety/Depression score: No restrictions

Exclusion Criteria:

- Abdominal surgery (except appendectomy or cholecystectomy)

- GI medications during the 48h prior to transit measurement

- Aspartate/Alanine transaminases >2 X Upper Limit of Normal (ULN)

- Other Medications except stable doses of estrogen, thyroid, low dose antidepressants of the dopaminergic or serotonergic class

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Sodium chenodeoxycholate (NaCDC)
500 or 1000 milligrams NaCDC per day each for a period of 4 days
Other:
Placebo
Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (3)

Lead Sponsor Collaborator
Mayo Clinic National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90. — View Citation

Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastro — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Colonic Geometric Center at 24 Hours (GC24) The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. after 4 days of treatment No
Secondary Colonic Transit at 48 Hours (GC48) The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. after 4 days of treatment No
Secondary Ascending Colon Emptying (AC t_1/2) after 4 days' treatment No
Secondary Stool Consistency The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. after 4 days' treatment No
Secondary Colonic Filling at 6 Hours Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time. after 4 days' treatment No
See also
  Status Clinical Trial Phase
Terminated NCT00742872 - Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome Phase 3
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Withdrawn NCT05321953 - The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation N/A
Not yet recruiting NCT06319729 - A Chinese Herbal Medicine for IBS-C Phase 2
Completed NCT01085643 - Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS) N/A
Completed NCT03150212 - Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype N/A
Recruiting NCT05757037 - Laser Acupuncture on Irritable Bowel Syndrome in Females N/A
Completed NCT05392439 - Effect of taVNS on Abdominal Pain and Other Symptoms in Constipation-predominant Irritable Bowel Syndrome N/A
Not yet recruiting NCT05921383 - Anorectal Manometry of Patients With Constipation Predominant IBS
Recruiting NCT05134584 - Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders Phase 4
Terminated NCT03336034 - Assessment of Responsiveness to Treatment by Experience Sampling Method
Not yet recruiting NCT04666155 - MOWOOT Device Treatment for Adults With Chronic Constipation N/A
Not yet recruiting NCT05941650 - To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome N/A
Completed NCT00945334 - Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome N/A
Terminated NCT00607971 - Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) Phase 3

External Links